SI0999832T1 - Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols - Google Patents

Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols

Info

Publication number
SI0999832T1
SI0999832T1 SI9830694T SI9830694T SI0999832T1 SI 0999832 T1 SI0999832 T1 SI 0999832T1 SI 9830694 T SI9830694 T SI 9830694T SI 9830694 T SI9830694 T SI 9830694T SI 0999832 T1 SI0999832 T1 SI 0999832T1
Authority
SI
Slovenia
Prior art keywords
carnitine
alkanoyl
long
chain alkanols
composition
Prior art date
Application number
SI9830694T
Other languages
English (en)
Slovenian (sl)
Inventor
Claudio Cavazza
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SI0999832T1 publication Critical patent/SI0999832T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
SI9830694T 1997-08-01 1998-07-09 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols SI0999832T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97RM000487A IT1294227B1 (it) 1997-08-01 1997-08-01 Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
PCT/IT1998/000190 WO1999006039A1 (en) 1997-08-01 1998-07-09 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols
EP98932504A EP0999832B1 (en) 1997-08-01 1998-07-09 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols

Publications (1)

Publication Number Publication Date
SI0999832T1 true SI0999832T1 (en) 2004-12-31

Family

ID=11405212

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830694T SI0999832T1 (en) 1997-08-01 1998-07-09 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols

Country Status (16)

Country Link
US (1) US6328998B1 (xx)
EP (1) EP0999832B1 (xx)
JP (1) JP4295429B2 (xx)
KR (1) KR100530878B1 (xx)
AT (1) ATE277611T1 (xx)
AU (1) AU741363B2 (xx)
CA (1) CA2295746C (xx)
DE (1) DE69826674T2 (xx)
DK (1) DK0999832T3 (xx)
ES (1) ES2229514T3 (xx)
HK (1) HK1028547A1 (xx)
IT (1) IT1294227B1 (xx)
NZ (1) NZ501967A (xx)
PT (1) PT999832E (xx)
SI (1) SI0999832T1 (xx)
WO (1) WO1999006039A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
IT1306722B1 (it) 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
US7214394B2 (en) * 2002-05-31 2007-05-08 Archer-Daniels-Midland Company Policosanol compositions, extraction from novel sources, and uses thereof
US20060166951A1 (en) * 2002-05-31 2006-07-27 Archer-Daniels-Midland Company Compositions and methods for sterol isolation and purification
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7649103B2 (en) * 2002-06-17 2010-01-19 Medestea Research And Production S.R.L. Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field
US20090196914A1 (en) * 2002-11-14 2009-08-06 Optime Therapeutics, Inc. Liposomal l-carnitine
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US7615641B2 (en) * 2004-07-20 2009-11-10 Sino Pharmaceuticals Corporation Long chain aliphatic alcohol derivatives and methods of making and using same
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
JPS6299323A (ja) * 1985-10-25 1987-05-08 Yoshihide Hagiwara 高脂血症剤
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
DE69026496D1 (de) * 1989-10-13 1996-05-15 Neurofit Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
JPH05103596A (ja) 1991-10-11 1993-04-27 Yukio Yanagimoto 陸上動物用体力増強剤及び陸上動物用飼料
JPH05103629A (ja) 1991-10-11 1993-04-27 Yukio Yanagimoto 体力増強剤
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
JPH05310563A (ja) * 1992-05-15 1993-11-22 Nippon Oil & Fats Co Ltd カルシトニン産生増強剤
JPH0825891B2 (ja) * 1993-06-25 1996-03-13 株式会社薬理学中央研究所 脱脂米胚芽由来のリパーゼインヒビター
US5560928A (en) * 1995-06-23 1996-10-01 Defelice; Stephen L. Nutritional and/or dietary composition and method of using the same
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi

Also Published As

Publication number Publication date
DE69826674D1 (de) 2004-11-04
WO1999006039A1 (en) 1999-02-11
HK1028547A1 (en) 2001-02-23
KR20010022449A (ko) 2001-03-15
ES2229514T3 (es) 2005-04-16
AU8240798A (en) 1999-02-22
NZ501967A (en) 2001-09-28
US6328998B1 (en) 2001-12-11
EP0999832B1 (en) 2004-09-29
DE69826674T2 (de) 2005-02-24
JP4295429B2 (ja) 2009-07-15
CA2295746C (en) 2007-11-20
ITRM970487A1 (it) 1999-02-01
ATE277611T1 (de) 2004-10-15
PT999832E (pt) 2004-12-31
CA2295746A1 (en) 1999-02-11
AU741363B2 (en) 2001-11-29
KR100530878B1 (ko) 2005-11-23
DK0999832T3 (da) 2005-01-17
EP0999832A1 (en) 2000-05-17
JP2001511447A (ja) 2001-08-14
IT1294227B1 (it) 1999-03-24

Similar Documents

Publication Publication Date Title
HK1028547A1 (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols.
CA2191645A1 (en) Pharmaceutical composition comprising l-carnitine or an alkanoyl l-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
CA2086429A1 (fr) Composition pharmaceutique ou cosmetique contenant en association un retinoide et un sterol
ZA9610508B (en) Pharmaceutical composition comprising l-carnitine or alkanoyl l-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders
BG102733A (en) New substituted cyclic amino acids as pharmaceutical forms
EP1520582A3 (en) Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
BR9810121A (pt) Utilização do acido petroselìnico nativo ou esterificado
CA2273298A1 (en) Product and method for the treatment of hyperlipidemia
GEP20001898B (en) Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
AU2192395A (en) Novel cationic phospholipids for transfection
BG109876A (en) APPLICATION OF L-CARNITIN ESTERS OR ALCANAILIC L-CARNITINES AS CATIONARY LIPIDS FOR INTRACULAR TRANSMISSION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
EP0795604A3 (en) Strains of bacteria with altered metabolism of bile acids and their use
EP1623708A3 (en) Pharmaceutical composition comprising acetyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
IT1307278B1 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
ES2099676A1 (es) Nuevo producto de fibra de cacao a base de cascara de cacao tostada.
NZ298141A (en) Treating lipid metabolism disorder using TCF-II
EP1062954A4 (en) METHOD FOR PRODUCING REGULATORS OF THE GLYCOLYTIC METABOLISM
PT1010429E (pt) Composicao farmaceutica em particular para uso dietetico constituida por um derivado de acido piruvico e extracto de laranja amarga nao madura
BR0007901A (pt) Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária
GR1003099B (el) Ουσιες, φυσικης ή συνθετικης προελευσης, που ανηκουν στις ομαδες των τερπενοειδων, πολυφαινολων και προανθοκυανιδων, για χρηση στην προληψη και θεραπεια καθε τυπου υπερχοληστεριναιμιας και διαταραχης λιπιδιων, σε ανθρωπους και ζωα
BR9714785A (pt) Composições desinfetantes e processos de desinfecção de superfìcies
ECSP972296A (es) Sintesis de benzo (f) quinolinonas
BR7700881U (pt) Papa pizza
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.